Asset profile
eloralintide
Peptide
Evidence outlook · registrational
Obesity: registrational readout pending
Entered Phase 3 on reliable signal mid-stage evidence. Registrational readout expected around 2028-01.
NCT06230523: Randomized, double-blind, placebo-controlled phase 2 in obesity and overweight (263 participants). Week-48 body-weight reductions ranged from 9.4% to 20.1% across eloralintide doses versus 0.4% on placebo, a separation many times larger than the reported error margins; percent change in body weight is the accepted registrational endpoint in obesity.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
71 competitors in this universe: 11 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 8 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Eloralintide: this drug | Phase 3 | Peptide | Amylin receptor | ||
| Amycretin | Phase 3 | Peptide | GLP-1 receptor, Amylin receptor | ||
| AZD6234 | Phase 3 | Peptide | Amylin receptor | ||
| Cagrilintide | Phase 3 | Peptide | Amylin receptor, Amylin/calcitonin receptor (dual) | ||
| Cagrilintide / Semaglutide (CagriSema) | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor | ||
| MET-097i | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor | ||
| Petrelintide | Phase 3 | Peptide | Amylin receptor, Amylin/calcitonin receptor (dual) | ||
| ABBV-295 | Phase 2 | Peptide | Amylin receptor | ||
| GUB-UCN2 | Phase 1/2 | Peptide | Amylin receptor | ||
| MET-233i | Phase 1/2 | Peptide | Amylin receptor | ||
| RM-718 | Phase 1/2 | Peptide | Amylin receptor | ||
| GUB014295 | Phase 1 | Peptide | Amylin receptor | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Naltrexone / Bupropion (Contrave) | Approved | Small molecule | Opioid receptor / dopamine (combination) | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | ||
| Orlistat (Xenical / Alli) | Approved | Small molecule | Pancreatic/gastric lipase |
…and 56 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
5 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(13 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
2027 (7)
March 2027 (2)
June 2027 (2)
August 2027 (1)
2028 (5)
January 2028 (1)
March 2028 (3)
June 2028 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.